Dapagliflozin/sitagliptin
| Combination of | |
|---|---|
| Dapagliflozin | SGLT-2 inhibitor |
| Sitagliptin | DPP-4 inhibitor |
| Clinical data | |
| Trade names | Sidapvia |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
Dapagliflozin/sitagliptin, sold under the brand name Sidapvia, is a fixed-dose combination anti-diabetic medication used for the treatment of type 2 diabetes.[1] It contains dapagliflozin, as propanediol monohydrate, a SGLT-2 inhibitor; and sitagliptin, as phosphate monohydrate, a DPP-4 inhibitor.[1] It is taken by mouth.[1]
References
- ^ a b c d e http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2024-PI-02050-1
- ^ "Sidapvia (AstraZeneca Pty Ltd)". Therapeutic Goods Administration (TGA). 1 July 2024. Retrieved 8 July 2024.
- ^ "Sidapvia 10/100 dapagliflozin 10 mg (as propanediol monohydrate)/sitagliptin 100 mg (as phosphate monohydrate) film coated tablets blister pack (405540)". Therapeutic Goods Administration (TGA). 8 June 2024. Retrieved 8 July 2024.
- ^ Dunleavy K (24 July 2023). "AstraZeneca enlists SK Chemicals to produce diabetes combo drug Sidapvia". Fierce Pharma. Retrieved 8 July 2024.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |